NKTR — NEKTAR THERAPEUTICS
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 906709 ·
Last close
$60.40
Market Cap
$2.06B
52W High
$109.00
52W Low
$33.40
ADV30
1,043,728
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 10,131,000 | — | — | -40,622,000 | — | 39,267,000 | — |
| Mar 2026 | 10,861,000 | — | -38,258,000 | -44,904,000 | 763,271,000 | 149,578,000 | 187,055,000 |
| Dec 2025 | 21,807,000 | 21,807,000 | -19,090,000 | -36,079,000 | 280,406,000 | 15,116,000 | 190,574,000 |
| Sep 2025 | 11,790,000 | 11,790,000 | -31,532,000 | -35,522,000 | 301,347,000 | 41,032,000 | 216,261,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-203,756,000
Investing CF
$-395,675,000
Financing CF
$710,108,000
CapEx
$-187,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-8.42
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-3,805,190,000
Inventory
$0
Receivables
$3,600,000
ST Investments
$419,026,000
EBIT TTM
$-123,056,000
Pretax Income TTM
$-152,208,000
Interest Exp TTM
$29,152,000
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$54,589,000
EBITDA
$-129,950,000
Free Cash Flow
$-134,766,368
Enterprise Value
$1,833,408,256
Total Cash
$684,340,992
Total Debt
$135,934,000
Shares Out
34,142,994
Trailing EPS
$-6.12
Book Value
$26.46
ROE
-35.8%
ROA
-12.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 55,232,000 | -130,771,000 | -164,076,000 | 280,406,000 | 190,574,000 | 89,832,000 | -208,511,000 |
| Dec 2024 | 98,427,000 | -129,918,000 | -118,961,000 | 303,850,000 | 243,113,000 | 60,737,000 | -175,709,000 |
| Dec 2023 | 90,122,000 | -135,225,000 | -276,056,000 | 398,033,000 | 267,046,000 | 130,987,000 | -192,606,000 |
| Dec 2022 | 92,055,000 | -240,236,000 | -368,198,000 | 710,600,000 | 343,962,000 | 366,638,000 | -304,007,000 |
TTM Snapshot
Revenues TTM
$105,757,000
NetIncome TTM
$-495,945,000
OpCashFlow TTM
$0
Assets (Latest)
$710,600,000
Forward EPS
$-10.84
Max Pain — expiry 2026-10-16
max pain strike: $65.00 · spot: $60.40 · call oi: 13,602 · put oi: 7,450
Expected Move to 2026-10-16:
±$7.85
(13.00%) —
implied range
$52.55 –
$68.25
· ATM straddle on $60.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TRVI | Trevi Therapeutics, Inc. | $2.05B | $14.40 | — |
| PRGO | PERRIGO Co plc | $2.09B | $15.10 | — |
| GLPGF | Lakefront Biotherapeutics NV | $2.09B | $31.95 | — |
| PVLA | PALVELLA THERAPEUTICS, INC. | $2.01B | $139.83 | — |
| BHVN | Biohaven Ltd. | $2.00B | $13.27 | — |
News headlines (Yahoo Finance, 1h cache)
Nektar Announces Three Oral Presentations for Rezpegaldesleukin at the European Academy of Dermatology & Venereology (EADV) Congress 2026
2026-09-28 12:00 · Yahoo
Nektar Therapeutics (NKTR) Dropped, So What Is Driving Attention Now?
2026-09-28 11:10 · Yahoo
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-25 20:15 · Yahoo
Sector Update: Healthcare Stocks Edge Higher in Afternoon Trading
2026-09-25 17:57 · Yahoo
Update: Nektar Wins $90 Million Jury Verdict Against Eli Lilly Over Rezpegaldesleukin Deal
2026-09-25 14:46 · Yahoo
Nektar Therapeutics stock rises on $90M jury verdict vs Lilly
2026-09-25 13:47 · Yahoo
Nektar’s (NKTR) Billion-Dollar Balance Sheet Faces A Multi-Year Test
2026-08-27 13:56 · Yahoo
Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
2026-08-25 12:30 · Yahoo
Nektar (NKTR) Q2 2026 Earnings Call Transcript
2026-08-20 23:34 · Yahoo
Nektar Therapeutics (NKTR) Could Be 52% Undervalued After Q2 Earnings Surprise
2026-08-15 02:09 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.